VF
FDMT icon

Virtu Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Virtu Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,368
Closed -$245K – 1807
2026
Q1 		$245K Buy
+26,368
New +$229K 0.01% 919
2025
Q3 		– Sell
-12,648
Closed -$47K – 1662
2025
Q2 		$47K Buy
+12,648
New +$44.5K ﹤0.01% 1148

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Virtu Financial's FDMT Position: Q2 2026 in Review

Virtu Financial sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 26,368 shares — an estimated $245K sold.

Virtu Financial first reported a position in FDMT in Q2 2025 and held it in 2 quarters. The position peaked at $245K in Q1 2026. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Virtu Financial reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 26,368 4D Molecular Therapeutics shares in Q2 2026, an estimated $245K.
  • Virtu Financial first reported a position in 4D Molecular Therapeutics in Q2 2025 and held it in 2 quarters.
  • Virtu Financial's 4D Molecular Therapeutics position peaked at $245K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.